PH24790A - Recombinant garma interferon - Google Patents

Recombinant garma interferon

Info

Publication number
PH24790A
PH24790A PH31568A PH31568A PH24790A PH 24790 A PH24790 A PH 24790A PH 31568 A PH31568 A PH 31568A PH 31568 A PH31568 A PH 31568A PH 24790 A PH24790 A PH 24790A
Authority
PH
Philippines
Prior art keywords
interferon
residue
garma
recombinant
hydrogen
Prior art date
Application number
PH31568A
Other languages
English (en)
Inventor
Patrick William Gray
Ernst Heinrich Rinderknecht
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27072811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH24790(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PH24790A publication Critical patent/PH24790A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/30—Signal or leader sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
PH31568A 1983-12-16 1984-12-12 Recombinant garma interferon PH24790A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56200983A 1983-12-16 1983-12-16
US06/584,217 US4855238A (en) 1983-12-16 1984-02-27 Recombinant gamma interferons having enhanced stability and methods therefor

Publications (1)

Publication Number Publication Date
PH24790A true PH24790A (en) 1990-10-30

Family

ID=27072811

Family Applications (1)

Application Number Title Priority Date Filing Date
PH31568A PH24790A (en) 1983-12-16 1984-12-12 Recombinant garma interferon

Country Status (23)

Country Link
US (4) US4855238A (lv)
EP (1) EP0146354B2 (lv)
JP (6) JPH0789935B2 (lv)
KR (1) KR940008978B1 (lv)
AT (1) ATE135405T1 (lv)
AU (1) AU597872B2 (lv)
CA (1) CA1341573C (lv)
CY (1) CY1945A (lv)
DE (1) DE3486424T3 (lv)
DK (1) DK166832B1 (lv)
ES (1) ES8801553A1 (lv)
FI (1) FI91884C (lv)
GR (1) GR82468B (lv)
HK (1) HK175996A (lv)
HU (1) HU202278B (lv)
IE (1) IE72494B1 (lv)
IL (1) IL73803A (lv)
LV (1) LV11633B (lv)
MY (1) MY102899A (lv)
NO (1) NO178789C (lv)
OA (1) OA07902A (lv)
PH (1) PH24790A (lv)
PT (1) PT79691A (lv)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
GB8406910D0 (en) * 1984-03-16 1984-04-18 Biogen Nv Gamma interferon
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ZA846554B (en) * 1983-09-20 1985-04-24 Hoffmann La Roche Immune interferon and method for its purification
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
JPS60172999A (ja) * 1983-12-20 1985-09-06 Suntory Ltd 新規な塩基性ポリペプチドおよびその製造法
DK168016B1 (da) * 1983-12-26 1994-01-17 Kyowa Hakko Kogyo Kk Derivat af humant interferon-gamma-polypeptid
EP0174999B1 (en) * 1984-03-16 1991-04-17 Biogen, Inc. Method for improving expression and method thereto
DE3414831A1 (de) * 1984-04-19 1985-10-31 Hoechst Ag, 6230 Frankfurt Herstellung von polypeptiden mit human-gammainterferon-aktivitaet
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
CA1302320C (en) * 1984-06-11 1992-06-02 Hideo Niwa Expression of human cromosomal interferon-_ in animal cells
JPS61108397A (ja) * 1984-10-31 1986-05-27 Green Cross Corp:The インタ−フエロン−γ蛋白質の製造法
JPS6156195A (ja) * 1985-03-01 1986-03-20 Asahi Chem Ind Co Ltd 新規生理活性ペプチド
US4873312A (en) * 1985-04-25 1989-10-10 Amgen Method for purifying interferon and composition of matter produced thereby
IE58766B1 (en) * 1985-04-30 1993-11-03 Takeda Chemical Industries Ltd Production of protein
DE3532134A1 (de) * 1985-09-10 1987-03-12 Basf Ag Verfahren zur herstellung von proteinen bestimmter n-terminaler struktur mit hilfe von prokaryonten
DE3536939A1 (de) * 1985-10-17 1987-04-23 Hoechst Ag Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten
AU612983B2 (en) * 1986-08-01 1991-07-25 Australian National University, The Recombinant vaccine
GB8619725D0 (en) * 1986-08-13 1986-09-24 Hoffmann La Roche Homogenous interferon fragments
US5157004A (en) * 1986-12-27 1992-10-20 Takeda Chemical Industries, Ltd. Polypeptides and production thereof
JP2653061B2 (ja) * 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法
DE3730331A1 (de) * 1987-09-10 1989-03-30 Basf Ag Neue polypeptide, verfahren zur herstellung, die vektoren dafuer und arzneimittel daraus
AT393690B (de) * 1987-10-08 1991-11-25 Hoffmann La Roche Homogene, rekombinante immun-interferonfragmente
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
DE68929273T2 (de) * 1988-08-24 2001-07-05 American Cyanamid Co., Wayne Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US6068994A (en) * 1989-08-07 2000-05-30 Chiron Corporation Ubiquitin expression system
BG52073B2 (en) * 1990-01-24 1996-04-30 Inst Molekuljarna Biolog Method for the preparation of recombinant human noncystein -interferon, free of n-end methionine
WO1992004377A1 (en) * 1990-08-31 1992-03-19 Schering Corporation HUMAN INTERFERON-η4-134, FUNCTIONAL EQUIVALENTS THEREOF AND METHODS OF USING AND COMPOSITIONS EMPLOYING THESE MATERIALS
DE4036856C1 (lv) * 1990-11-19 1992-05-27 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De
US5227158A (en) * 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
AU7116394A (en) * 1993-07-01 1995-01-24 Merck & Co., Inc. Culture medium for recombinant yeasts
TW249202B (lv) * 1993-08-13 1995-06-11 Ciba Gerigy Corp
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
JP5030329B2 (ja) 1998-04-02 2012-09-19 ジェネンテック， インコーポレイテッド 心臓肥大の処置
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
RU2140285C1 (ru) 1999-01-25 1999-10-27 Гапонюк Петр Яковлевич Противовирусное средство - капли в нос "гриппферон"
US6475796B1 (en) * 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
AU5026100A (en) * 1999-05-20 2000-12-12 Scios Inc. Vascular endothelial growth factor dimers
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
IL152804A0 (en) * 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
KR20040007413A (ko) * 2000-11-03 2004-01-24 바이오메디신즈 인코포레이티드 단기 및 장기 약물 약량측정 방법
KR100951409B1 (ko) * 2001-01-09 2010-04-07 베일러 리서치 인스티튜트 수지상 세포로의 단핵세포 분화를 억제하는 조성물 및 이를 포함하는 키트
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
WO2003039455A2 (en) * 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
US20050002900A1 (en) * 2001-11-06 2005-01-06 Grace Wong Method of treating estrogen responsive breast cancer
CN100438870C (zh) * 2001-11-09 2008-12-03 精达制药公司 ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途
WO2003049760A1 (en) * 2001-12-07 2003-06-19 Intermune, Inc. Compositions and method for treating hepatitis virus infection
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
EP1539814A2 (en) * 2002-07-03 2005-06-15 Maxygen Holdings Ltd. c/o Close Brothers (Cayman) Limited Full-length interferon gamma polypeptide variants
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20070092488A1 (en) * 2003-05-16 2007-04-26 Intermune Inc. Methods of treating idiopathic pulmonary fibrosis
US20070172446A1 (en) 2003-05-16 2007-07-26 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
NZ546347A (en) 2003-10-14 2009-11-27 Intermune Inc Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US8906676B2 (en) * 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2006141263A (ja) * 2004-11-18 2006-06-08 Kyoto Univ （ｒ）−ヒドロキシニトリルリアーゼの製造方法
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1877434A2 (en) * 2005-05-04 2008-01-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TR201807756T4 (tr) 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
AU2008247815B2 (en) 2007-05-02 2012-09-06 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US8243103B2 (en) * 2009-05-29 2012-08-14 Exelis, Inc. Laser aiming spot distinguishing methods and apparatus
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
CA2788607C (en) * 2010-02-01 2018-03-20 Digna Biotech,S.L. Process for the production of interferon alpha 5
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
CN104363892A (zh) 2012-02-07 2015-02-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing a TLR agonist and methods of use
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
BR112018074352B1 (pt) 2016-06-01 2021-11-30 Infectious Disease Research Institute Partículas de nanoalume contendo um agente de dimensionamento
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
WO2019040740A1 (en) 2017-08-23 2019-02-28 Wayne State University IMMUNO IMAGING IN VIVO OF INTERFERON GAMMA
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
CA3168761A1 (en) 2020-03-19 2021-09-23 Minna HASSINEN Temperature-responsive virus storage system
BR112022019660A2 (pt) 2020-03-30 2022-11-29 Trizell Ltd Composições e métodos para tratamento de câncer

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7404589A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het stabiliseren van interferon.
NL7404590A (nl) * 1974-04-03 1975-10-07 Stichting Rega V Z W Werkwijze voor het reactiveren van interferon.
US4332892A (en) * 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
JPS5598118A (en) * 1979-01-18 1980-07-25 Hayashibara Takeshi Preparation of type-2 interferon and drug containing the same
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4460685A (en) * 1980-05-29 1984-07-17 New York University Method of enhancing the production of human γ Interferon
US4341761A (en) * 1980-07-25 1982-07-27 E. I. Du Pont De Nemours And Company Antibodies to immunogenic peptides and their use to purify human fibroblast interferon
US4311639A (en) * 1980-07-25 1982-01-19 E. I. Du Pont De Nemours And Company Immunogenic interferon peptides
FI64813C (fi) * 1980-12-31 1984-01-10 Ilkka Antero Palva Foerfarande foer producering av ett utvalt aeggviteaemne och vid foerfarandet anvaenda rekombinantplasmidvektorer
US4382027A (en) * 1981-08-18 1983-05-03 Meloy Laboratories, Inc. Purification of human immune interferon
IL65475A0 (en) * 1981-04-17 1982-07-30 Meloy Lab Production of immune interferon and its mrna
US4404188A (en) * 1981-07-29 1983-09-13 Massachusetts General Hospital Purified Mullerian Inhibiting Substance and method of purification
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US5582824A (en) * 1981-10-19 1996-12-10 Genentech, Inc. Recombinant DES-CYS-TYR-CYS human immune interferon
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
JPS58110548A (ja) * 1981-12-24 1983-07-01 Asahi Chem Ind Co Ltd 新規な生理活性ペプチド
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
EP0088540A3 (en) * 1982-02-22 1984-10-17 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
ZA83768B (en) * 1982-03-01 1983-10-26 Hoffmann La Roche Homogeneous human immune interferon and process therefor
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
US4681848A (en) * 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
IL69851A0 (en) * 1982-09-30 1983-12-30 Japan Found Cancer Novel dna and recombinant plasmid containing the same
WO1984002129A1 (en) * 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
US4432895A (en) * 1982-11-24 1984-02-21 Hoffmann-La Roche Inc. Monomeric interferons
US4485017A (en) * 1982-12-22 1984-11-27 Cetus Corporation Isolation of human interferon by immunosorbent and high performance liquid chromatography
JPH0740925B2 (ja) * 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
JPS59169494A (ja) * 1983-03-17 1984-09-25 Takeda Chem Ind Ltd 新規組み換えｄｎａおよびその用途
US4599306A (en) * 1983-04-15 1986-07-08 Amgen Monoclonal antibodies which specifically bind to human immune interferon
IL71951A0 (en) * 1983-06-01 1984-09-30 Hoffmann La Roche Polypeptides having interferon activity,their preparation and pharmaceutical compositions containing them
IL72773A0 (en) * 1983-08-29 1984-11-30 Meloy Lab Production of immune interferon and its mrna
US4681930A (en) * 1983-09-20 1987-07-21 Hoffmann-La Roche Inc. Immune interferon and a method for its extraction and purification
US4604284A (en) * 1983-09-20 1986-08-05 Hoffmann-La Roche Inc. Homogeneous immune interferon fragment
US4476049A (en) * 1983-09-20 1984-10-09 Hoffmann-La Roche Inc. Method for the extraction of immune interferon
JPS6079000A (ja) * 1983-10-04 1985-05-04 Takeda Chem Ind Ltd ヒトγ型インタ−フエロン単量体の製造法
JPH0788398B2 (ja) * 1983-10-17 1995-09-27 サントリー株式会社 新規生理活性ポリペプチドおよびその製造法
JPS60118196A (ja) * 1983-11-30 1985-06-25 Takeda Chem Ind Ltd インタ−フェロンの製造法
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
IL75302A0 (en) * 1984-06-06 1985-09-29 Takeda Chemical Industries Ltd Novel polypeptide and production thereof
JP2653061B2 (ja) 1986-12-27 1997-09-10 武田薬品工業株式会社 新規ポリペプチドおよびその製造法

Also Published As

Publication number Publication date
AU597872B2 (en) 1990-06-14
FI91884B (fi) 1994-05-13
FI91884C (fi) 1994-08-25
KR940008978B1 (ko) 1994-09-28
EP0146354B2 (en) 2001-10-24
IE843203L (en) 1985-06-16
HU202278B (en) 1991-02-28
HUT36187A (en) 1985-08-28
US5595888A (en) 1997-01-21
CY1945A (en) 1984-12-14
MY102899A (en) 1993-03-31
IL73803A (en) 1997-09-30
DK600984D0 (da) 1984-12-14
US5574137A (en) 1996-11-12
JPH0794477B2 (ja) 1995-10-11
JPH0919295A (ja) 1997-01-21
JPH10210985A (ja) 1998-08-11
NO845042L (no) 1985-06-17
JPH03201979A (ja) 1991-09-03
DK166832B1 (da) 1993-07-19
AU3663584A (en) 1985-06-20
FI844934A0 (fi) 1984-12-13
DE3486424D1 (de) 1996-04-18
DK600984A (da) 1985-08-22
OA07902A (en) 1986-11-20
JPH08151399A (ja) 1996-06-11
ES8801553A1 (es) 1988-02-16
LV11633B (en) 1997-08-20
JPS60202899A (ja) 1985-10-14
JP2545206B2 (ja) 1996-10-16
IE72494B1 (en) 1997-04-23
KR850004273A (ko) 1985-07-11
EP0146354B1 (en) 1996-03-13
US6497871B1 (en) 2002-12-24
JPH07173196A (ja) 1995-07-11
ATE135405T1 (de) 1996-03-15
GR82468B (en) 1985-03-27
PT79691A (en) 1985-01-01
DE3486424T3 (de) 2002-06-06
US4855238A (en) 1989-08-08
JP2886145B2 (ja) 1999-04-26
JPH0789935B2 (ja) 1995-10-04
CA1341573C (en) 2008-05-13
NO178789C (no) 1996-06-05
HK175996A (en) 1996-09-27
NO178789B (no) 1996-02-26
EP0146354A2 (en) 1985-06-26
EP0146354A3 (en) 1986-03-19
JP2719128B2 (ja) 1998-02-25
ES538620A0 (es) 1988-02-16
IL73803A0 (en) 1985-03-31
DE3486424T2 (de) 1996-09-12
LV11633A (lv) 1996-12-20
FI844934L (fi) 1985-06-17
JP2580491B2 (ja) 1997-02-12

Similar Documents

Publication Publication Date Title
PH24790A (en) Recombinant garma interferon
ES8802235A1 (es) Procedimiento para preparar un polipeptido
IL79085A (en) Hybrid interferons having an amino acid sequence composed of sub-sequences of human lymphoblastoid interferons lyifn-alpha-2 and lyifn-alpha-3,their preparation and pharmaceutical compositions containing them
MX166499B (es) Interferon recombinante inmune humano y composicion farmaceutica que lo incluye
AU558966B2 (en) Interferon and amino acid as stabilizer
DE3586833D1 (de) Synergistische mischungen von interferonen und tumor-nekrose-faktor.
GR79236B (lv)
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
IL74426A (en) Atrial peptides and pharmaceutical compositions comprising them
ATE44652T1 (de) Zubereitung mit gehalt an stabilisiertes polypeptid mit gamma-interferon aktivitaet.
ATE46348T1 (de) Neue, physiologisch aktive polypeptide und deren herstellungsverfahren.
DE69106407D1 (de) Verfahren zur Herstellung von rekombinantem menschlichem gamma-Interferon ohne Cystein und ohne Methionin am N-Terminal.
IL96513A0 (en) Polypeptide comprising the amino acid sequence of recombinant human immune interferon
IL77019A0 (en) Novel microbes transformed with a replicable microbial expression vehicle capable of expressing a polypeptide comprising the amino acid sequence of mature human fibroblast interferon